Bio-Rad Laboratories (BIO) Stock Forecast & Price Target

Bio-Rad Laboratories is positioned for a constructive re-rating as management’s restructuring and operating-expense actions aim to lift margins toward a mid-teens target by 2028-2029, above the current 2029 modeling assumption of 13% and consistent with operating leverage at roughly 3% organic growth. Its fundamentals should also improve as idiosyncratic headwinds in process chromatography fade after 2026, supporting a rebound in sales growth in 2027, while stabilization in end markets and a consumables-heavy ddPCR mix help reduce earnings volatility. Finally, the company’s ~33% Sartorius stake provides significant hidden asset value, and optionality should increase in mid-2028 when the Sartorius Trust terminates, enhancing the appeal of the stock’s valuation relative to peers.

Bio-Rad Laboratories is viewed negatively because its sales and margin trajectory remain under pressure, with investors already discounting the possibility that recovery in life science tools demand may continue to disappoint after years of false starts. The company also faces structural and company-specific headwinds, including ongoing ddPCR share losses to Qiagen, mixed M&A execution, heavy restructuring over the past five years, and a Q1 2026 earnings call that signaled further business retooling. Its valuation is additionally vulnerable to further erosion if confidence weakens or the Sartorius stake is marked down more aggressively, while governance concerns tied to the Schwartz family’s control may limit shareholder alignment and strategic flexibility.